Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | BUB1 | O43683 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | GNRHR | P30968 | 1/20 | 0.39 |
| ▸ | PDE5A | O76074 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SLC26A6 | Q9BXS9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3841604 | 0.83 | KMT2A (0.43) | ALDH1A1POLBKDM4EKMT2AMEN1 | |
| SCHEMBL597857 | 0.83 | ALDH1A1 (0.44) | ALDH1A1POLBKDM4EKMT2AMEN1 | |
| SCHEMBL16796453 | 0.78 | ALDH1A1 (0.48) | ALDH1A1POLBKDM4EKMT2AMEN1 | |
| SCHEMBL20211712 | 0.77 | ALDH1A1 (0.49) | ALDH1A1POLBKDM4EKMT2AMEN1 | |
| SCHEMBL2921176 | 0.76 | SMN1; SMN2 (0.52) | ALDH1A1POLBKDM4EKMT2AMEN1 | |
| SCHEMBL16082690 | 0.75 | SMN1; SMN2 (0.52) | ALDH1A1POLBKDM4EKMT2AMEN1 | |
| SCHEMBL29831320 | 0.75 | SMN1; SMN2 (0.52) | ALDH1A1POLBKDM4EKMT2AMEN1 | |
| SCHEMBL17610985 | 0.74 | P2RY14 (0.50) | ALDH1A1POLBKDM4EKMT2AMEN1 | |
| SCHEMBL17610956 | 0.74 | SMN1; SMN2 (0.47) | ALDH1A1POLBKDM4EKMT2AMEN1 | |
| SCHEMBL15780014 | 0.73 | SMN1; SMN2 (0.54) | ALDH1A1POLBKDM4EKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114400-B2 | Aza-bicyclic compounds and their use as stimulators of soluble guanylate cyclase | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-14 | — | — | US | disclosed |
| US-8114400-B2 | Aza-bicyclic compounds and their use as stimulators of soluble guanylate cyclase | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-14 | — | — | US | disclosed |
| US-8114400-B2 | Aza-bicyclic compounds and their use as stimulators of soluble guanylate cyclase | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-14 | — | — | US | disclosed |
| US-20110038857-A1 | NOVEL AZA-BICYCLIC COMPOUNDS AND THEIR USE AS STIMULATORS OF SOLUBLE GUANYLATE CYCLASE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-02-17 | — | — | US | disclosed |
| US-20110038857-A1 | NOVEL AZA-BICYCLIC COMPOUNDS AND THEIR USE AS STIMULATORS OF SOLUBLE GUANYLATE CYCLASE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-02-17 | — | — | US | disclosed |
| US-20110038857-A1 | NOVEL AZA-BICYCLIC COMPOUNDS AND THEIR USE AS STIMULATORS OF SOLUBLE GUANYLATE CYCLASE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-02-17 | — | — | US | disclosed |
| WO-2008061657-A1 | NOVEL AZA-BICYCLIC COMPOUNDS AND THEIR USE AS STIMULATORS OF SOLUBLE GUANYLATE CYCLASE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110038857-A1 | NOVEL AZA-BICYCLIC COMPOUNDS AND THEIR USE AS STIMULATORS OF SOLUBLE GUANYLATE CYCLASE | GUCY1A2, PDE2A, GUCY1B2 | ALDH1A1 2455/4885POLB 2666/4885KDM4E 2271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.